Leo Wealth LLC Purchases 3,680 Shares of Gilead Sciences, Inc. $GILD

Leo Wealth LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,897 shares of the biopharmaceutical company’s stock after acquiring an additional 3,680 shares during the period. Leo Wealth LLC’s holdings in Gilead Sciences were worth $1,828,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter worth approximately $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the second quarter valued at approximately $30,000. MTM Investment Management LLC lifted its stake in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the period. Millstone Evans Group LLC boosted its holdings in shares of Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. Finally, Y.D. More Investments Ltd bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $37,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 299,280 shares of company stock valued at $42,820,550. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. TD Cowen lifted their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Truist Financial increased their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Citigroup restated a “buy” rating on shares of Gilead Sciences in a report on Friday, March 6th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Argus upped their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $139.71 on Monday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The stock’s 50 day moving average is $145.09 and its 200-day moving average is $129.65. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $173.41 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.83 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.